Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2025.1595951 Immunology Correction Corrigendum: Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial Abdellatif Abdul 1 Zhao Lin 2 Obermeyer Katie 2 Vranic Zana 2 Marder Brad A. 2 * Scandling John D. 3 1 Department of Medicine, Division of Nephrology at CLS Health and Baylor College of Medicine, Houston, TX, United States 2 Rare Disease Unit, Amgen Inc. (formerly Horizon Therapeutics), Thousand Oaks, CA, United States 3 Division of Nephrology, Stanford School of Medicine, Stanford, CA, United States

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Brad A. Marder, bmarder@amgen.com

03 04 2025 2025 16 1595951 18 03 2025 25 03 2025 Copyright © 2025 Abdellatif, Zhao, Obermeyer, Vranic, Marder and Scandling 2025 Abdellatif, Zhao, Obermeyer, Vranic, Marder and Scandling

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial by Abdellatif A, Zhao L, Obermeyer K, Vranic Z, Marder BA and Scandling JD (2025). Front. Immunol. 16:1516146. doi: 10.3389/fimmu.2025.1516146 gout kidney transplant urate quality of life renal function blood pressure Amgen10.13039/100002429 section-in-acceptance Alloimmunity and Transplantation

In the published article, the reference for “The high impact of gout on lowering patient QOL is well established, and these effects are more pronounced in KT recipients” was incorrectly written as “40”. It should be “14”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.